MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
ADMA Biologics Operating Cycle 2011-2026 | ADMA
Annual Operating Cycle ADMA Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 391 | 336 | 393 | 495 | 566 | 600 | 533 | 191 | 220 | 323 | 339 | - | 301 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 600 | 191 | 391 |
Quarterly Operating Cycle ADMA Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 386 | 381 | 350 | - | 297 | 362 | 417 | - | 394 | 390 | 403 | - | 493 | 558 | 558 | - | 578 | 569 | 532 | - | 745 | 706 | 440 | - | 656 | 510 | 411 | 184 | 215 | 203 | 176 | - | 177 | 370 | 4.5 K | - | 1.43 K | 1.24 K | 41.7 | - | 45.5 | 64.4 | 39.7 | - | 25.6 | 23.4 | 11.2 | - | - | 20 | 21 | - | 9.9 | 15.5 | 406 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.5 K | 9.9 | 461 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
173 | $ 3.58 | 0.42 % | $ 1.07 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.79 | - | $ 4.31 M | China |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 6.59 | -0.6 % | $ 180 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
BioCardia
BCDA
|
101 | $ 1.29 | 1.57 % | $ 27.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
Anika Therapeutics
ANIK
|
325 | $ 14.36 | - | $ 210 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
111 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
360 | $ 2.64 | - | $ 16.6 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |